DailyMed
Cure8 regulatory brief
DailyMed label update for ADALIMUMAB
Medications
Adalimumab
Anti-TNF
Biosimilars
Regulatory Update
Adult patients
Pediatric Patients
Clinicians
Why This Matters
This is an official prescribing-label update for an adalimumab biosimilar used to treat Crohn’s disease and ulcerative colitis, including pediatric indications and dosing. Changes to indications or pediatric dosing and safety warnings can affect prescribing and patient counseling.
Who Should Pay Attention
Adults and pediatric patients with Crohn’s disease or ulcerative colitis, caregivers, and clinicians who prescribe or monitor anti‑TNF therapy
Study Snapshot
Story typeRegulatory
Evidence typeRegulatory update
Source depthMetadata only
What To Know
The document is the official prescribing label (DailyMed) for an adalimumab biosimilar and includes dosing regimens for induction and maintenance in Crohn’s disease and ulcerative colitis, pediatric dosing tables, warnings about infections and rare malignancies, and other standard prescribing sections.
It notes limitations of use (for patients who lost response to TNF blockers) and specific pediatric dosing changes in recent major changes.
If you are a patient reading this label: focus on the patient-specific sections and the medication guide link provided by DailyMed; dosing and safety details are written for clinical use and should be discussed with your prescriber.
If you are a clinician: refer to the full prescribing information for exact dosing (including weight-based pediatric dosing), contraindications, boxed warnings, and monitoring recommendations.
Keep In Mind
DailyMed provides the official FDA-approved label text and is intended as a prescriber- and patient-facing regulatory resource. Labels describe approved uses, dosing, and safety warnings but do not present new clinical trial results. Discuss any label changes with your healthcare provider.
Source Details
Review the original publication for the complete reporting, methods, and context.
Regulatory update
Evidence type derived from source or registry metadata.
PublicationDailyMed
Study typeDrug Label Update
Indexed viaDailyMed
Source typeDrug label record
PublishedJul 22, 2026, 12:00 AM
Content availableMetadata only
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
DailyMed label update for AMJEVITA
An updated drug label for AMJEVITA affects people with Crohn's disease, ulcerative colitis, and other immune conditions because it defines FDA‑approved uses, dosing schedules (including pediatric dosing), and safety...
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
A new ustekinumab biosimilar (SELARSDI) is now available in the U.S. for Crohn’s disease and ulcerative colitis, which may expand treatment options and affect access or cost for patients on biologic therapy.
When are biologic drugs an option for Crohn’s disease?
Biologics are a common and important treatment option for people with moderate to severe Crohn’s disease; knowing when they’re used and their potential risks helps patients discuss treatment choices with their care team.